Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy

Science

Volumn 282, Issue 5386, 1998, Pages 103-107

  Neumann, Avidan U ^a   Lam, Nancy P ^a   Dahari, Harel ^a   Gretch, David R ^a   Wiley, Thelma E ^a   Layden, Thomas J ^a   Perelson, Alan S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CORRELATION FUNCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING; VIRION; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; KINETICS; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRION; VIRUS REPLICATION;

EID: 0032475822     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5386.103     Document Type: Article

References (45)

1. A. M. Di Bisceglie, Lancet 351, 351 (1998); J. L. Brown, ibid., p. 78.
2. A. M. Di Bisceglie, Lancet 351, 351 (1998); J. L. Brown, ibid., p. 78.
3. M. Peters, Semin. Liver Dis. 9, 235 (1989).
4. D. D. Ho et al., Nature 373, 123 (1995); X. Wei et al., ibid., p. 117; A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, Science 271, 1582 (1996); A. S. Perelson et al., Nature 387, 188 (1997).
5. D. D. Ho et al., Nature 373, 123 (1995); X. Wei et al., ibid., p. 117; A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, Science 271, 1582 (1996); A. S. Perelson et al., Nature 387, 188 (1997).
6. D. D. Ho et al., Nature 373, 123 (1995); X. Wei et al., ibid., p. 117; A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, Science 271, 1582 (1996); A. S. Perelson et al., Nature 387, 188 (1997).
7. D. D. Ho et al., Nature 373, 123 (1995); X. Wei et al., ibid., p. 117; A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, Science 271, 1582 (1996); A. S. Perelson et al., Nature 387, 188 (1997).
8. M. A. Nowak et al., Proc. Natl. Acad. Sci. U.S.A. 93, 4398 (1996).
9. S. Zeuzem et al., Hepatology 23, 366 (1996); S. Zeuzem et al., ibid. 28, 245 (1998).
10. S. Zeuzem et al., Hepatology 23, 366 (1996); S. Zeuzem et al., ibid. 28, 245 (1998).
11. N. P. Lam et al., ibid. 26, 226 (1997).
12. F. C. Bekkering et al., ibid., p. 1691; N. P. Lam et al., ibid., p. 1692; K. Yashi et al., J. Infect. Dis. 177, 1475 (1998).
13. F. C. Bekkering et al., ibid., p. 1691; N. P. Lam et al., ibid., p. 1692; K. Yashi et al., J. Infect. Dis. 177, 1475 (1998).
14. F. C. Bekkering et al., ibid., p. 1691; N. P. Lam et al., ibid., p. 1692; K. Yashi et al., J. Infect. Dis. 177, 1475 (1998).
15. HCV genotypes were determined by a modification of the nested PCR procedure of Okamoto et al. [J. Gen. Virol. 73, 673, (1992)] and confirmed by restriction fragment length polymorphism analysis of the 5′ noncoding region.
16. Standard criteria for inclusion and exclusion of patients to IFN treatment were applied. Informed consent was obtained from all patients after the nature and the possible consequences of the study were explained to them. Data from four patients who were nonresponders were not used (Table 1), because their dynamics could not be fit with the same model as the responding patients. Detailed clinical information on these patients will be given separately (N. P. Lam et al., unpublished data).
17. Six of the patients who received 10 mIU (2A to 2F) had treatment discontinued for 1 week before they continued on the 5-mIU daily regime.
18. All serum samples (collected 0, 2, 4, 7, 10, 14, 19, and 24 hours after the first injection of IFN on day 0; 5, 10, and 24 hours after the second injection on day 1; and days 2, 3, 4, 5, 7, 9, 11, 12, and 14 before IFN injection) were separated from whole blood within 2 to 4 hours of venipuncture, divided into aliquots, and stored at -70°C.
19. 6 copies per milliliter in all samples of the period analyzed.
20. 6 copies per milliliter in all samples of the period analyzed.
21. The nonparametric Wilcoxon rank sum test was used to determine statistical significance of differences in viral fraction and slopes between dosing groups. The Spearman nonparametric test was used to assess the correlation between continuous variables. Significance was established at P < 0.03.
22. max) - can be used without significantly changing the results presented here.
23. 1/2 = ln(2)/C′, where c and ε are given in Table 1.
24. 0 = sp/cδ - d/δ.
25. T. T. Nguyen et al., J. Viral Hepatitis 3, 75 (1996).
26. The logarithm of Eq. 4 (or Eq. 5 as appropriate) was fit to the logarithm of the viral load data by a nonlinear least-squares method using the DNLS1 subroutine from the Common Los Alamos Software Library, which is based on a finite-difference Levenberg-Marquardt algorithm. Fits were made separately to the bDNA and to the Superquant viral load data wherever possible (12), and the average of the parameter estimates was reported. Standard errors were calculated by a bootstrap method [B. Efron and R. Tibshirani, Stat. Sci. 1, 54 (1986)] in which experiments were simulated 100 times.
27. T. Fukumoto et al., Hepatotogy 24, 1351 (1996).
28. 7 per milliliter observed in our patients.
29. S. Khakoo et al., Br. J. Clin. Pharmacol., in press.
30. In Lam et al. (6) this delay was not noticed, probably because of less frequent sampling.
31. N. Fausto, in Hepatology: A Textbook of Liver Disease, T. Boyer and D. Zakim, Eds. (Saunders, Philadelphia, ed. 3, 1996), pp. 32-58.
32. 2 ≈ εδ, and A ≈ ε.
33. D. R. Nelson et al., J. Immunol. 158, 1473 (1997); K. Hiroishi et al., Hepatology 25, 705 (1997).
34. D. R. Nelson et al., J. Immunol. 158, 1473 (1997); K. Hiroishi et al., Hepatology 25, 705 (1997).
35. B. Rehermann et al., J. Clin. Invest. 98, 1432 (1996); D. K. Wong et al., J. Immunol. 160, 1479 (1998).
36. B. Rehermann et al., J. Clin. Invest. 98, 1432 (1996); D. K. Wong et al., J. Immunol. 160, 1479 (1998).
37. D. R. Nelson et al., Hepatology 28, 225 (1998).
38. M. Martell et al., J. Virol. 66, 3225 (1992); D. R. Gretch and S. J. Polyak, in Hepatitis C Virus: Genetic Heterogeneity and Viral Load, Groupe Français d'Etudes Moleculaires des Hepatites, Eds. (John Libbey Eurotext, Paris, 1997), p. 57.
39. M. Martell et al., J. Virol. 66, 3225 (1992); D. R. Gretch and S. J. Polyak, in Hepatitis C Virus: Genetic Heterogeneity and Viral Load, Groupe Français d'Etudes Moleculaires des Hepatites, Eds. (John Libbey Eurotext, Paris, 1997), p. 57.
40. S. J. Polyak et al., J. Infect. Dis. 175, 1101 (1997); J. M. Pawlotsky et al., J. Virol. 72, 2795 (1998); S. J. Polyak et al., ibid., p. 4288.
41. S. J. Polyak et al., J. Infect. Dis. 175, 1101 (1997); J. M. Pawlotsky et al., J. Virol. 72, 2795 (1998); S. J. Polyak et al., ibid., p. 4288.
42. S. J. Polyak et al., J. Infect. Dis. 175, 1101 (1997); J. M. Pawlotsky et al., J. Virol. 72, 2795 (1998); S. J. Polyak et al., ibid., p. 4288.
43. R. De Francesco et al., Second International Conference on Therapies for Viral Hepatitis, Hawaii, December 1997 (abstr. 021); A. Molla et al., ibid. (abstr. 023).
44. R. De Francesco et al., Second International Conference on Therapies for Viral Hepatitis, Hawaii, December 1997 (abstr. 021); A. Molla et al., ibid. (abstr. 023).
45. We thank the patients for their participation in the study, B. Goldstein for the use of his nonlinear fitting package, and A. Talal and J. M. Pawlotsky for helpful discussions. Portions of this work were performed under the auspices of the U.S. Department of Energy. Supported by the committee for the advancement of research of Bar-Ilan University; the Santa Fe Institute; Schering Plough Corporation, Kenilworth, NJ; the Joseph P. Sullivan and Jeanne M. Sullivan Foundation; and NIH grants RR06555, A1/DK41320-2, and A139049-2.